Work

Epigenetic inhibition of adaptive bypass responses to lapatinib by targeting BET Bromodomains

Year: 2015

Type: article

Abstract: The characterization of kinases as oncogenic drivers has led to more than 30 FDA-approved targeted kinase inhibitors for cancer treatment. Unfortunately, these therapeutics fail to have clinical durability because of adaptive responses from the kinome and transcriptome that bypass inhibition of the targeted pathway. In our recent work, we describe a method to prevent these adaptive responses at an epigenetic level, generating a durable response to kinase inhibition.

Source: Molecular & Cellular Oncology

DOI: 10.1080/23723556.2015.1052182

Authors: Timothy J. Stuhlmiller, Samantha M. Miller, Gary L. Johnson

Institutions: University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center

Language: English

Topic: Protein Degradation and Inhibitors

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Institutes of Health, National Cancer Institute, National Institute of General Medical Sciences